Information Provided By: 
Fly News Breaks for April 2, 2019
ILMN, PACB
Apr 2, 2019 | 06:25 EDT
Stephens analyst Drew Jones downgraded Pacific Biosciences of California (PACB) to Equal Weight from Overweight while raising his price target for the shares to $8 from $4.50. The shares are within 10% of the looming purchase price by Illumina (ILMN), Jones tells investors in a research note. He believes all public commentary suggests the deal remains on track to close in mid-2019.
News For PACB;ILMN From the Last 2 Days
There are no results for your query PACB;ILMN
